Executive summary of the KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease: known knowns and known unknowns

Adeera Levin, Sofia B. Ahmed, Juan Jesus Carrero, Bethany Foster, Anna Francis, Rasheeda K. Hall, Will G. Herrington, Guy Hill, Lesley A. Inker, Rümeyza Kazancıoğlu, Edmund Lamb, Peter Lin, Magdalena Madero, Natasha McIntyre, Kelly Morrow, Glenda Roberts, Dharshana Sabanayagam, Elke Schaeffner, Michael Shlipak, Rukshana ShroffNavdeep Tangri, Teerawat Thanachayanont, Ifeoma Ulasi, Germaine Wong, Chih Wei Yang, Luxia Zhang, Karen A. Robinson, Lisa Wilson, Renee Wilson, Bertram L. Kasiske, Michael Cheung, Amy Earley, Paul E. Stevens

Research output: Contribution to journalArticlepeer-review

Abstract

The Kidney Disease: Improving Global Outcomes (KDIGO) Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease (CKD) updates the KDIGO 2012 guideline and has been developed with patient partners, clinicians, and researchers around the world, using robust methodology. This update, based on a substantially broader base of evidence than has previously been available, reflects an exciting time in nephrology. New therapies and strategies have been tested in large and diverse populations that help to inform care; however, this guideline is not intended for people receiving dialysis nor those who have a kidney transplant. The document is sensitive to international considerations, CKD across the lifespan, and discusses special considerations in implementation. The scope includes chapters dedicated to the evaluation and risk assessment of people with CKD, management to delay CKD progression and its complications, medication management and drug stewardship in CKD, and optimal models of CKD care. Treatment approaches and actionable guideline recommendations are based on systematic reviews of relevant studies and appraisal of the quality of the evidence and the strength of recommendations which followed the “Grading of Recommendations Assessment, Development, and Evaluation” (GRADE) approach. The limitations of the evidence are discussed. The guideline also provides practice points, which serve to direct clinical care or activities for which a systematic review was not conducted, and it includes useful infographics and describes an important research agenda for the future. It targets a broad audience of people with CKD and their healthcare, while being mindful of implications for policy and payment.

Original languageEnglish (US)
Pages (from-to)684-701
Number of pages18
JournalKidney international
Volume105
Issue number4
DOIs
StatePublished - Apr 2024

Keywords

  • CKD
  • KDIGO
  • chronic kidney disease
  • evaluation
  • guideline
  • management

ASJC Scopus subject areas

  • Nephrology

Fingerprint

Dive into the research topics of 'Executive summary of the KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease: known knowns and known unknowns'. Together they form a unique fingerprint.

Cite this